Get the Stockscreener App
0.69
2.99%
0.02
Iterum Therapeutics Plc stock is traded at $0.69, with a volume of 266.28K.
It is up +2.99% in the last 24 hours and up +2.88% over the past month.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
See More
Previous Close:
$0.67
Open:
$0.69
24h Volume:
266.28K
Relative Volume:
0.32
Market Cap:
$32.55M
Revenue:
-
Net Income/Loss:
$-24.08M
P/E Ratio:
-0.8049
EPS:
-0.8572
Net Cash Flow:
$-14.75M
1W Performance:
+1.85%
1M Performance:
+2.88%
6M Performance:
-37.27%
1Y Performance:
-43.44%
1-Day Range:
$0.6831
$0.70
1-Week Range:
$0.6431
$0.70
52-Week Range:
$0.6108
$3.02
Iterum Therapeutics Plc Stock (ITRM) Company Profile
Name
Iterum Therapeutics Plc
Sector
Industry
Phone
(872) 225-6077
Address
3 DUBLIN LANDINGS, DUBLIN 1
Compare ITRM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ITRM
Iterum Therapeutics Plc
|
0.6901 | 32.19M | 0 | -24.08M | -14.75M | -0.8572 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.97 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
632.67 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.67 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.64 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
181.94 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Iterum Therapeutics Plc Stock (ITRM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-21 | Upgrade | Gabelli & Co | Sell → Hold |
| Mar-15-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-02-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-21-20 | Downgrade | Gabelli & Co | Buy → Sell |
| Dec-11-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-21-19 | Initiated | H.C. Wainwright | Buy |
View All
Iterum Therapeutics Plc Stock (ITRM) Latest News
Can Iterum Therapeutics plc stock sustain market leadershipTake Profit & Real-Time Chart Pattern Alerts - newser.com
Visual analytics tools that track Iterum Therapeutics plc performancePortfolio Return Report & Stock Portfolio Risk Management - newser.com
Sentiment analysis tools applied to Iterum Therapeutics plcJuly 2025 Momentum & Technical Pattern Based Signals - newser.com
Using portfolio simulators with Iterum Therapeutics plc includedWeekly Trade Analysis & Risk Controlled Daily Trade Plans - newser.com
Reversal indicators forming on Iterum Therapeutics plc stock2025 Trade Ideas & Weekly Breakout Opportunity Watchlist - newser.com
What to expect from Iterum Therapeutics plc in the next 30 daysQuarterly Trade Report & Proven Capital Preservation Methods - newser.com
Will Iterum Therapeutics plc see short term momentumWeekly Trend Recap & Short-Term Swing Trade Alerts - newser.com
Combining machine learning predictions for Iterum Therapeutics plcProfit Target & Risk Controlled Stock Alerts - newser.com
Why Iterum Therapeutics plc stock appeals to analystsEarnings Miss & Smart Money Movement Tracker - newser.com
Published on: 2025-10-29 21:40:27 - newser.com
Is Iterum Therapeutics plc stock vulnerable to regulatory risksJuly 2025 Recap & Low Risk Growth Stock Ideas - newser.com
Published on: 2025-10-28 17:51:32 - fcp.pa.gov.br
Is Iterum Therapeutics plc stock a safe buy before earningsJuly 2025 Levels & Capital Protection Trading Alerts - fcp.pa.gov.br
How Iterum Therapeutics plc stock performs after earnings2025 Volume Leaders & Daily Risk Controlled Trade Plans - newser.com
Iterum Therapeutics Plc Stock (ITRM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.68%
0.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):